Edgewise Therapeutics Is A Biopharmaceutical Company Based In Bouldercoloradofocused On Developing Innovative Therapies For Serious Skeletal And Cardiac Muscle Diseasesfounded In 2017The Company Aims To Address The Unmet Needs Of Patients And Families Affected By These Conditions By Advancing Its Understanding Of Muscle Biology The Company Specializes In Discovering And Commercializing Treatments For Muscle Disordersits Product Pipeline Includes Edg 5506An Oral Small Molecule In Phase Ii Trials For Dystrophinopathies Like Duchenne Muscular Dystrophyedg 7500A Selective Cardiac Sarcomere Modulator In Phase I Trials For Hypertrophic Cardiomyopathyand Sevasemtena First In Class Fast Skeletal Myosin Inhibitor Being Explored For Various Muscular Dystrophiesedgewise Therapeutics Is Committed To Improving The Lives Of Those Affected By Muscle Diseases Through Patient Centered Therapies And A Strong Focus On Scientific Inquiry
